Healthcare > Pharmaceuticals & Biotechnology
•2438 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (2438)
| Company | Market Cap | Price |
|---|---|---|
|
IMUX
Immunic, Inc.
Immunic's lead programs are oral, small-molecule therapeutics (e.g., vidofludimus calcium and IMU-856).
|
$71.68M |
$0.72
-3.27%
|
|
ASRT
Assertio Holdings, Inc.
ROLVEDON and related oncology-supportive care products position Assertio in Biotech - Oncology as its growth drivers.
|
$71.36M |
$0.74
-1.25%
|
|
TCRX
TScan Therapeutics, Inc.
Directly related to cell therapy products (TCR-T therapies) and platform-enabled manufacturing via ImmunoBank/T-Plex.
|
$70.17M |
$1.24
-0.40%
|
|
XBIT
XBiotech Inc.
Company develops oncology therapies using True Human monoclonal antibodies, aligning with the Biotech - Oncology tag.
|
$69.82M |
$2.22
-3.06%
|
|
NTRB
Nutriband Inc.
Direct AVERSA drug-delivery platform enabling abuse-deterrent transdermal patches (lead product AVERSA Fentanyl) and related patch technologies.
|
$69.38M |
$6.55
+5.31%
|
|
SIGY
Sigyn Therapeutics, Inc.
Company’s cancer-related therapeutic platform focus places it in Biotech - Oncology.
|
$68.37M |
$2.00
|
|
AKYA
Akoya Biosciences, Inc.
Engagement in companion diagnostics through clinical collaborations (e.g., Acrivon, NeraCare).
|
$64.26M |
$1.29
|
|
CRVO
CervoMed Inc.
Neflamapimod is an orally administered, small-molecule therapeutic, aligning with the 'Oral Small Molecule Therapeutics' category.
|
$61.09M |
$7.57
+7.76%
|
|
ACET
Adicet Bio, Inc.
Directly develops allogeneic cell therapies (gamma delta T cells) for autoimmune diseases and cancer as its primary product platform.
|
$60.38M |
$0.73
+0.12%
|
|
IOBT
IO Biotech, Inc.
IO Biotech's lead candidate is a therapeutic cancer vaccine (off-the-shelf cancer vaccines) and IO102-IO103 is built on a vaccine platform.
|
$59.99M |
$0.88
-3.35%
|
|
DRRX
DURECT Corporation
Larsucosterol is described as an orally bioavailable small molecule therapeutic and the lead program for DURECT, targeting alcohol-associated hepatitis.
|
$59.29M |
$1.91
|
|
HOWL
Werewolf Therapeutics, Inc.
Werewolf Therapeutics develops conditionally activated immunotherapies for cancer, aligning with Biotech - Oncology.
|
$58.78M |
$1.24
-5.73%
|
|
GUTS
Fractyl Health, Inc. Common Stock
Rejuva gene therapy platform (RJVA-001) and related candidates (RJVA-002) classify as Biotech - Gene Therapy, a core product line aimed at durable disease modification.
|
$58.28M |
$1.17
-2.10%
|
|
IPA
ImmunoPrecise Antibodies Ltd.
Core antibody discovery platform offering de novo antibody design and epitope mapping via LENSai/HYFT.
|
$57.82M |
N/A
|
|
ICCC
ImmuCell Corporation
The company develops immunology-based therapeutics for animal health, including passive immunity and antimicrobial approaches used in calves and dairy cows.
|
$56.12M |
$6.09
-1.93%
|
|
ETST
Earth Science Tech, Inc.
ETST's core pharmaceutical operations include compounding pharmacies (RxCompound, Mister Meds) providing outsourced drug manufacturing services.
|
$55.82M |
$0.24
|
|
EQ
Equillium, Inc.
Equillium's pipeline focuses on immunology/inflammatory diseases, aligning with Immunology Therapeutics.
|
$55.36M |
$1.49
-4.19%
|
|
GANX
Gain Therapeutics, Inc.
GT-02287 is a small-molecule therapeutic candidate, aligning with the major product category of oral small-molecule therapeutics.
|
$54.39M |
$1.79
-2.45%
|
|
COEP
Coeptis Therapeutics, Inc.
GEAR Cell Therapy Platform is a core cell therapy biotech asset.
|
$54.22M |
$15.28
-0.97%
|
|
CUE
Cue Biopharma, Inc.
CUE Biopharma is developing oncology-focused immunotherapies and cancer programs, aligning with Biotech - Oncology.
|
$54.06M |
$0.78
+8.50%
|
|
KRON
Kronos Bio, Inc.
Kronos Bio's core activity is oncology-focused biotechnology with a pipeline of small-molecule oncology agents, fitting Biotech - Oncology.
|
$53.65M |
$0.88
|
|
INKT
MiNK Therapeutics, Inc.
MiNK's lead product agenT-797 and pipeline comprise allogeneic, off-the-shelf iNKT cell therapies, a direct Cell Therapy business.
|
$53.61M |
$14.05
+4.46%
|
|
UNCY
Unicycive Therapeutics, Inc.
Lead programs Oxylanthanum Carbonate (OLC) and UNI-494 are oral small-molecule therapeutics targeting kidney disease and hyperphosphatemia/acute kidney injury.
|
$53.56M |
$4.57
+2.82%
|
|
OSTX
OS Therapies Incorporated
OSTX's lead therapy OST-HER2 is a cancer immunotherapy targeting oncology indications.
|
$52.54M |
$1.82
-2.67%
|
|
KPTI
Karyopharm Therapeutics Inc.
Karyopharm's core business is oncology-focused biotechnology/pharmaceuticals, including the approved cancer therapy XPOVIO (selinexor) and an oncology pipeline.
|
$52.44M |
$5.67
-6.51%
|
|
SNTI
Senti Biosciences, Inc.
Directly develops cancer therapies and immuno-oncology agents, notably SENTI-202 CAR-NK therapies targeting AML.
|
$52.16M |
$2.02
+1.00%
|
|
IPSC
Century Therapeutics, Inc.
Directly develops iPSC-derived cell therapies (CAR-iT, CAR-iNK, Allo-Evasion-enabled products) and related platforms.
|
$51.70M |
$0.63
+5.37%
|
|
PSTV
Plus Therapeutics, Inc.
Core product: radiopharmaceutical therapy using Rhenium-186 nanoliposomes for CNS cancers.
|
$51.39M |
$0.50
-3.07%
|
|
ANL
Adlai Nortye Ltd. American Depositary Shares
Adlai Nortye is a clinical-stage biotechnology company focused on oncology therapies, establishing Biotech - Oncology as its core domain.
|
$51.24M |
$1.52
+9.35%
|
|
CBUS
Cibus, Inc.
Reported contract research revenue indicates direct R&D services provided to clients alongside platform licensing.
|
$49.69M |
$1.45
+0.35%
|
|
ABVC
ABVC BioPharma, Inc.
ABVC's pipeline includes oncology therapeutics derived from plant compounds and cancer-focused programs.
|
$49.65M |
$2.90
-2.03%
|
|
BMEA
Biomea Fusion, Inc.
Direct product category: Biomea Fusion is developing oral small molecule therapeutics, including icovamenib and BMF-650.
|
$49.60M |
$1.28
-2.65%
|
|
NRXP
NRx Pharmaceuticals, Inc.
NRx's pipeline centers on neuropsychiatric drug development (NRX-100, NRX-101) targeting suicidal depression and bipolar depression.
|
$49.27M |
$2.85
-0.18%
|
|
BRNS
Barinthus Biotherapeutics plc
Company is pivoting to immunology/inflammation therapeutics and is advancing T‑cell immunotherapies (SNAP-TI), with VTP-1000 for celiac disease as lead candidate.
|
$48.00M |
$1.24
+4.20%
|
Showing page 18 of 25 (2438 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
